Navigation Links
XTL Biopharmaceuticals Announces Receipt of NASDAQ Notice of Delisting
Date:1/28/2009

VALLEY COTTAGE, N.Y., Jan. 28 /PRNewswire-FirstCall/ -- XTL Biopharmaceuticals Ltd. (Nasdaq: XTLB, TASE: XTL) today announced that on January 27, 2009 it received a Staff Determination Letter (the "Letter") from The Nasdaq Stock Market ("Nasdaq") notifying the Company that the staff of Nasdaq's Listing Qualifications Department determined, using its discretionary authority under Nasdaq Marketplace Rule 4300, that the Company's American Depository Shares ("ADRs") would be delisted from Nasdaq. The Letter further stated that Nasdaq would suspend trading in the Company's ADRs at the opening of trading on February 5, 2009 and then file a Form 25-NSE with the Securities and Exchange Commission ("SEC") to deregister the Company's ADRs, unless the Company appeals Nasdaq's delisting determination. Nasdaq's determination to delist the ADRs was based on Nasdaq's belief that the Company was a public shell and that the Company does not meet the stockholder's equity requirement or any of its alternatives.

The Letter also indicated that, in accordance with the procedures set out in Marketplace Rule 4800 Series, the Company would have seven (7) calendar days, or until February 3, 2009, to appeal the delisting from Nasdaq to a Listing Qualifications Panel. At this time, the Company does plan to appeal the delisting from Nasdaq. There can be no assurance that the appeal will be successful.


'/>"/>
SOURCE XTL Biopharmaceuticals Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
5. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
6. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
7. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
8. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
10. Morria Biopharmaceuticals Plc Appoints Dr. Johnson Lau and Dr. David Sidransky to Board of Directors
11. XTL Biopharmaceuticals Ltd. AGM / EGM Postponed Until October 2, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... ... news outlet had initiated coverage on NuLife Sciences. According to Soulstring, NuLife Sciences ... transplant industry, focused on kidney transplant technology that integrates proprietary recellularization processes intended ...
(Date:8/23/2017)... ... August 23, 2017 , ... ... ability to manipulate 3D models of pediatric patients’ neuroanatomy and accurately tailor radiation ... of the Journal of Medical Imaging. The advance is reported in an article ...
(Date:8/23/2017)... ... August 22, 2017 , ... Mettler-Toledo, one of the market leaders in product ... . This turnkey system inspects labels, prints, and packaging properties fully automatically, and, thanks ... lines and extended as needed. , The high-end version of the V2630 was ...
(Date:8/23/2017)... (PRWEB) , ... August 22, 2017 , ... ... announced that two market innovators, Munich Re , one of the world’s ... (IQT), the strategic investor that accelerates the development of technologies to support the ...
Breaking Biology Technology:
(Date:8/23/2017)... 2017  The general public,s help is being enlisted in what,s thought ... in and on the human body –and are believed to affect health.  ... The Microbiome Immunity Project is the ... with the gut. The project's goal is to help advance scientific knowledge ... ...
(Date:8/15/2017)... HAMPTON, Va. , Aug. 15 2017   ivWatch LLC ... effectiveness of intravenous (IV) therapy, today announced receipt of its ISO ... (QMS) developed by the International Organization for Standardization (ISO®). ... ivWatch Model 400 Continuous Monitoring device for ... "This ...
(Date:7/20/2017)... DAL ) customers now can use fingerprints instead of their boarding ... ... biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May at the ... to allow eligible Delta SkyMiles Members who are enrolled in CLEAR to ...
Breaking Biology News(10 mins):